

# Life expectancy can increase by up to 10 years following sustained shifts towards healthier diets in the United Kingdom

Received: 22 March 2023

Accepted: 29 September 2023

Published online: 20 November 2023

 Check for updates

Lars T. Fadnes<sup>1,2</sup>✉, Carlos Celis-Morales<sup>3,4</sup>, Jan-Magnus Økland<sup>1,5</sup>, Solange Parra-Soto<sup>3,6</sup>, Katherine M. Livingstone<sup>7</sup>, Frederick K. Ho<sup>8</sup>, Jill P. Pell<sup>8</sup>, Rajiv Balakrishna<sup>1</sup>, Elaheh Javadi Arjmand<sup>1,2</sup>, Kjell Arne Johansson<sup>1,2,5</sup>, Øystein A. Haaland<sup>1,5</sup> & John C. Mathers<sup>9</sup>

Adherence to healthy dietary patterns can prevent the development of non-communicable diseases and affect life expectancy. Here, using a prospective population-based cohort data from the UK Biobank, we show that sustained dietary change from unhealthy dietary patterns to the Eatwell Guide dietary recommendations is associated with 8.9 and 8.6 years gain in life expectancy for 40-year-old males and females, respectively. In the same population, sustained dietary change from unhealthy to longevity-associated dietary patterns is associated with 10.8 and 10.4 years gain in life expectancy in males and females, respectively. The largest gains are obtained from consuming more whole grains, nuts and fruits and less sugar-sweetened beverages and processed meats. Understanding the contribution of sustained dietary changes to life expectancy can provide guidance for the development of health policies.

In the United Kingdom, unhealthy diets are estimated to cause more than 75,000 premature deaths each year, including almost 17,000 deaths in the age group 15–70 years<sup>1</sup>. Evidence on the mortality benefits of food choices is essential for the United Kingdom to achieve Sustainable Development Goal target 3.4, which is to reduce premature mortality from non-communicable diseases by one-third by 2030 (ref. 2) Internationally, the Global Burden of Diseases and Injuries consortium and the EAT–*Lancet* commission encourage healthy eating and quantify the population health that is associated with unhealthy eating<sup>3–5</sup>. Furthermore, Public Health England and the UK Government encourage the population to follow the diet pattern recommended in the Eatwell Guide to achieve a healthy and balanced diet<sup>6</sup>.

Life expectancy is a measure of expected years an individual has left to live and is a commonly used metric for population health. Higher adherence to the recommendations of the Eatwell Guide is associated with reduced mortality in the United Kingdom<sup>7</sup>, but it is not known how a sustained improvement in dietary patterns translates into gains in life expectancy at different stages of life. Estimating such gains in life expectancy would provide policymakers with a measure of the health gains that are possible in a population and provide guidance on which policies would be the most effective. Furthermore, health personnel would also benefit in identifying key risks related to unhealthy dietary patterns with the highest potential for gain when guiding people to prioritize relevant behaviour changes. In addition, most people do not

<sup>1</sup>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. <sup>2</sup>Bergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. <sup>3</sup>School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.

<sup>4</sup>Education, Physical Activity and Health Research Unit, University Católica del Maule, Talca, Chile. <sup>5</sup>Bergen Centre for Ethics and Priority Setting, University of Bergen, Bergen, Norway. <sup>6</sup>Department of Nutrition and Public Health, Universidad del Bío-Bío, Chillán, Chile. <sup>7</sup>Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia. <sup>8</sup>School of Health and Wellbeing, University of Glasgow, Glasgow, UK. <sup>9</sup>Human Nutrition and Exercise Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK. ✉e-mail: [lars.fadnes@uib.no](mailto:lars.fadnes@uib.no)

	Q1 (lowest)	Q2	Q3 (typical)	Q4	Q5 (highest)
Whole grains	1	0.78 (0.74–0.81)	0.77 (0.73–0.8)	0.82 (0.78–0.86)	0.82 (0.79–0.86)
Vegetables	1	0.95 (0.9–0.99)	0.94 (0.9–0.98)	0.92 (0.87–0.96)	0.93 (0.89–0.97)
Fruit	1	0.88 (0.84–0.91)	0.84 (0.79–0.89)	0.85 (0.81–0.89)	0.86 (0.82–0.9)
Nuts	1	0.82 (0.76–0.89)	0.91 (0.8–1.03)	0.89 (0.73–1.08)	0.81 (0.2–3.24)
Legumes	1	0.91 (0.83–0.98)	1.02 (0.87–1.21)	1.02 (0.6–1.72)	0.72 (0.1–5.11)
Fish	1	0.97 (0.92–1.02)	0.96 (0.92–1.00)	1.03 (0.98–1.09)	0.99 (0.94–1.03)
Egg	1	0.82 (0.73–0.93)	0.85 (0.78–0.93)	0.90 (0.83–0.96)	1.08 (0.95–1.23)
Milk	1	0.99 (0.85–1.16)	0.98 (0.85–1.13)	0.95 (0.82–1.1)	0.93 (0.8–1.08)
Refined grains	1	1.20 (1.12–1.28)	1.17 (1.11–1.23)	1.23 (1.18–1.28)	1.16 (1.11–1.21)
Meat, red	1	1.02 (0.95–1.09)	1.05 (0.99–1.13)	1.18 (1.07–1.29)	1.21 (1.08–1.37)
Meat, processed	1	1.02 (0.96–1.08)	1.13 (1.06–1.2)	1.25 (1.14–1.37)	1.47 (1.27–1.69)
Meat, white	1	0.97 (0.90–1.04)	0.91 (0.85–0.98)	1.00 (0.88–1.15)	0.97 (0.71–1.33)
Sugar-sweetened beverages	1	0.91 (0.83–1)	1.02 (0.9–1.16)	1.22 (0.98–1.52)	1.59 (1.1–2.31)

**Fig. 1 | Hazard ratio for all-cause mortality per food group for each quintile (Q1–Q5) among UK Biobank participants.** Data are presented as hazard ratios and their 95% confidence intervals. The reference groups were the lowest quintile of intake for each food group. The analyses were adjusted for age, sex, area-based socio-demographic deprivation, smoking, alcohol consumption and physical

activity level. The unhealthy categories are shown in red, the longevity associated are shown in green and dark green, and the Eatwell recommendations are shown in blue. The dark green category had large uncertainties; thus, the robust version of the healthiest dietary patterns is in green (not dark green).


adhere to healthy eating guidelines<sup>8</sup>, with research showing that less than 0.1% of the UK population adheres to all recommendations of the Eatwell Guide<sup>7</sup>. Therefore, it is important to estimate the gains in life expectancy that are expected from different types of dietary change and various degrees of adherence to the recommendations.

Recently, we developed a model for estimating age- and sex-specific gains or losses in life expectancy following sustained change (that is, dietary changes for remaining lifespan) in the consumption of major food groups with measured intakes<sup>9</sup>. In this paper, we use this model to estimate life expectancy gains from a sustained change from median or unhealthy dietary patterns in the United Kingdom to the longevity-associated dietary pattern, or to the recommendations of the Eatwell Guide.

The median dietary patterns in the United Kingdom were categorized as the intake level with the mid-quintile intake of each of the food groups from the UK Biobank data, from 467,354 participants. The longevity-associated dietary patterns were the quintiles for each food group with the lowest mortality risk estimates or second lowest if the confidence intervals were very wide (Fig. 1). For the unhealthy eating pattern, we used the quintiles for each food group with the highest mortality association, while for the Eatwell Guide, we chose the quintiles of daily intakes fitting best the Eatwell Guide. A detailed description of the methodology is described in Supplementary Information.

## Results

Our results showed that the longevity-associated dietary pattern had moderate intakes of whole grains, fruit, fish and white meat; a high intake of milk and dairy, vegetables, nuts and legumes; a relatively low intake of eggs, red meat and sugar-sweetened beverages; and a low intake of refined grains and processed meat (Fig. 1). Analyses adjusting also for body mass index and energy (Supplementary Information) showed slight reductions in inverse associations with mortality for whole grains, vegetables and fruits, reductions in positive associations with mortality for red meat, and stronger inverse associations for both nuts and white meat. For several of the food groups associated with reduced mortality, the lowest intake quintiles were substantially different from the other quintiles. The unhealthy dietary pattern (that is, the quintile with the highest mortality associations) contained no or limited amounts of whole grains, vegetables, fruits, nuts, legumes, fish, milk and dairy, and white meat and substantial intakes of processed meat, eggs, refined grains and sugar-sweetened beverages. The strongest positive associations with mortality were for sugar-sweetened beverages and processed meat, while the strongest inverse associations with mortality were for whole grains and nuts.



**Fig. 2 | Expected life years gained from dietary changes.** Expected life years gained after changing from unhealthy median dietary patterns (red), changing from median dietary patterns to the Eatwell Guide (blue) and changing from the Eatwell Guide to longevity-associated dietary patterns (green) for 40-year-old female and male adults (F40 and M40, respectively) and 70-year-old female and male adults (F70 and M70, respectively) from the United Kingdom. Both core-adjusted models (adjusted for age, sex, socio-demographic area, smoking, alcohol consumption and activity level) and mediation models (adjusted for energy and body mass index (BMI plus E)) are presented.

We present life expectancy estimates with uncertainty intervals (UI, indicating the lowest and highest population means that are likely) associated with various dietary patterns in Fig. 2, Table 1 and Supplementary Information. The life expectancy (that is, the estimated remaining years to live) of a 40-year-old with a median dietary pattern was 44.7 years for females and 41.5 years for males. Similarly, the life expectancy of a 70-year-old with a median dietary pattern was 17.6 years for females and 15.5 years for males. Estimated gains from simulated sustained dietary change from a median UK diet pattern to the longevity-associated diet pattern were 3.1 years (UI 1.3–4.9 years) for 40-year-old females and 3.4 years (UI 1.4–5.3 years) for 40-year-old males. Correspondingly, for sustained change to the Eatwell dietary

**Table 1 | Life expectancy associated with various dietary patterns among UK females and males aged 40 and 70 years, and life expectancy gains with uncertainty intervals (UI) changes in dietary patterns**

Group	MUK (years)	UUK (years)	EUK (years)	LUK (years)	MUK → LUK (UI years)	UUK → LUK (UI years)	MUK → EUK (UI years)	UUK → EUK (UI years)
UK females, 40 years old	44.7	37.4	46	47.8	3.1 (1.3, 4.9)	10.4 (8.2, 11.3)	1.3 (0.1, 2.4)	8.6 (6.8, 10.2)
UK females, 70 years old	17.6	13.9	18.4	19.3	1.7 (0.7, 2.6)	5.4 (4.4, 6.0)	0.7 (0.0, 1.3)	4.4 (3.6, 5.4)
UK males, 40 years old	41.5	34	42.9	44.8	3.4 (1.4, 5.3)	10.8 (8.8, 12.0)	1.4 (0.1, 2.6)	8.9 (7.2, 10.8)
UK males, 70 years old	15.5	12.2	16.2	17.1	1.6 (0.7, 2.5)	5.0 (4.2, 5.6)	0.7 (0.0, 1.2)	4.0 (3.4, 5.1)
UK females, 40 years old <sup>a</sup>	44.7	39.7	46.1	47.7	3.1 (1.3, 5.1)	8.0 (5.3, 9.7)	1.5 (−0.2, 2.9)	6.4 (4.1, 8.8)
UK females, 70 years old <sup>a</sup>	17.6	15.1	18.4	19.3	1.7 (0.7, 2.7)	4.3 (2.8, 5.2)	0.8 (−0.1, 1.5)	3.4 (2.2, 4.7)
UK males, 40 years old <sup>a</sup>	41.5	36.3	43	44.8	3.3 (1.4, 5.4)	8.4 (5.7, 10.4)	1.6 (−0.2, 3.1)	6.7 (4.3, 9.3)
UK males, 70 years old <sup>a</sup>	15.4	13.1	16.2	17.1	1.6 (0.7, 2.6)	3.9 (2.7, 4.9)	0.8 (−0.1, 1.5)	3.1 (2.1, 4.3)

<sup>a</sup>Extensively adjusted models also adjusted for energy and body mass index. Dietary changes presented: MUK → LUK: from median UK diet (MUK) to longevity-associated diet patterns (LUK); UUK → LUK: from unhealthy UK diet patterns (UUK) to LUK; MUK → EUK: from MUK to the Eatwell Guide dietary pattern (EUK); UUK → EUK: from UUK to EUK.

pattern, estimated gains were 1.3 years (UI 0.1–2.4 years) for females and 1.4 years (UI 0.1–2.6 years) for males. Estimated gains from sustained dietary changes from an unhealthy UK diet pattern to the longevity-associated diet pattern were 10.4 years (UI 8.2–11.3 years) for 40-year-old females and 10.8 years (UI 8.8–12.0 years) for 40-year-old males. Correspondingly, estimated gains from sustained dietary changes from an unhealthy UK diet pattern to the longevity-associated diet pattern were 5.4 years (UI 4.4–6.0 years) for 70-year-old females and 5.0 years (UI 4.2–5.6 years) for 70-year-old males.

Estimated gains from simulated sustained dietary changes from an unhealthy UK diet pattern to full adherence to the Eatwell Guide were 8.6 years (UI 6.8–10.2 years) for 40-year-old females and 8.9 years (UI 7.2–10.8 years) for 40-year-old males. Corresponding gains for 70-year-old females and males were 4.4 years (UI 3.6–5.4 years) and 4.0 years (UI 3.4–5.1 years), respectively.

In sensitivity analyses, sex-stratified analyses of food groups and associations with mortality generally showed similar associations across the sexes except for white meat, which seemed to be more beneficial among females. A range of other sensitivity analyses are presented in Supplementary Information. To reduce potential reverse causation, we performed a landmark analysis that excluded events that occurred within the previous 2 years.

## Discussion

In this paper, we present a method for estimating changes in life expectancy following changes in food choices, considering correlation between mortality and food group intakes, and effect delay. Such estimates may be useful particularly for policy purposes and for underpinning both guidance and interventions for improving public health. Our results indicate that UK adults aged 40 years with median dietary patterns can expect to gain approximately 3 years in life expectancy from sustained changes to the longevity-associated dietary patterns. Importantly, the estimated gain in life expectancy is approximately a decade for those shifting from the unhealthiest to the longevity-associated dietary patterns. Overall, the bigger the changes made towards healthier dietary patterns, the larger the expected gains in life expectancy are.

Consuming less sugar-sweetened beverages and processed meats and eating more whole grains and nuts were estimated to result in the biggest improvements in life expectancy. Sensitivity analysis also adjusting for body mass index and energy consumption indicated that body mass index and energy consumption might partially mediate and/or confound a possible beneficial effect between life expectancy and whole grains, vegetables and fruits, and inversely for red meat and eggs. For white meat, associations were stronger when adjusting for energy intake and body mass index, while the situation was mixed for legumes.

These estimates correspond well with meta-analyses on associations between intakes of food groups and mortality<sup>10–15</sup>. Our estimates from the UK Biobank are also strengthened by meta-analyses of randomized trials on the consumption of various food groups and scoring of biomarkers for disease<sup>16</sup>, mirroring our estimates with nuts, legumes and whole grains performing most beneficially and sugar-sweetened beverages and red meat performing worst. We have also presented estimated health gains associated with adhering to the Eatwell Guide recommendations, showing that the Eatwell Guide does well on the longevity perspective. The life expectancy gains from changes from unhealthy eating to the Eatwell Guide achieve 82–83% of the potential compared with those from sustained change to longevity-associated patterns, which strengthens the evidence base for the promotion of the dietary targets in the Eatwell Guide in public health guidance and interventions. The Eatwell Guide might also be a more realistic target for dietary changes than the statistically set longevity-associated dietary patterns.

Unsurprisingly, predicted gains in life expectancy are lower when the dietary change is initiated at older ages, but these remain substantial. For example, we estimated that people at the age of 70 years could expect to benefit from about half of the life expectancy gain predicted for adults at the age of 40 years, equivalent to a gain in 1.5 years when optimizing median dietary patterns and 4–5 years for those shifting from the unhealthiest dietary patterns. The UK population currently has a life expectancy at birth of 83.6 years for females and 79.9 years for males, and a 3 year gain in life expectancy associated with changes from median to longevity-optimized dietary patterns from the age of 40 years (ref. 17). Life expectancies have steadily increased over time<sup>18</sup>, and the observed increase is parallel to the changes in life expectancy observed in the United Kingdom over the past 15 years<sup>17</sup>. A large shift towards healthy dietary patterns could contribute substantially to meeting Sustainable Development Goal target 3.4 that aims to cut premature mortality by one-third.

The governmental food strategy in the United Kingdom to address chronic diseases emphasizes a shared responsibility, with the industry having a responsibility to promote and supply healthier foods, the government having a role in making targeted regulatory interventions to support change, and individual consumers being empowered with better information about healthier choices and thus demanding and seeking healthier foods<sup>19</sup>. With respect to potential policy actions, a recent paper presented approaches to address the substantial inequalities in health in the United Kingdom<sup>20</sup>. The paper argues for five principles, including healthy-by-default and easy-to-use initiatives, long-term and multisector action, locally designed focus, targeting disadvantaged communities and matching of resources to need. The paper further identifies various actions that could contribute to improvements,

such as health-oriented food taxes and subsidies aiming to reduce the cost of healthy foods but not that of unhealthy foods. Other actions were related to improving food environments in school, public and working places by removing vending machines and banning the sale of sugar-sweetened beverages and snacks high in fat, sugar or salt. Such policy measures, informed by the up-to-date estimates on potential gains in life expectancy that we provide in this paper, could guide the deployment of resources to improve healthy eating patterns across the population.

Limitations of our study include correlation between the associations between food groups and mortality. We addressed this through model adjustments presenting a conservative model as the main analyses. As for most cohort studies, confounders can have an impact. However, we have adjusted our core models for several potential confounders such as age, sex, area-based socio-demographic deprivation, smoking, alcohol consumption and physical activity level. We have also added sensitivity analyses investigating for mediation and possible confounding from body mass index and energy intake. Our models are based on population data with the uncertainty measure being on the population-level mean. Nevertheless, even though the individual uncertainty is likely to be larger than uncertainty at the group level, one could expect the mean life expectancy differences of groups of individuals with similar characteristics but variations in group size to be comparable (with uncertainty being higher in smaller groups). Thus, our estimates could be useful also in clinical settings. We model sustained and prolonged dietary changes. However, maintaining lifestyle changes over time with dietary improvements can be challenging, and for many, dietary patterns fluctuate over time. We have not modelled potential changes in life expectancy of fluctuating changes. Furthermore, unhealthy and longevity-associated dietary patterns could be seen as dietary 'constructs' (as associations between dietary patterns and mortality are used to set these). This is not necessarily overlapping with typically presented dietary patterns such as the Mediterranean or the Nordic diets. Furthermore, the UK Biobank does not measure consumption of rice, which is particularly important for many migrant groups. Overall, the UK Biobank data under-represent non-white populations compared to the UK population. Even though the UK Biobank data contain about nearly half a million participants in our analyses, the size of the data is not sufficient to achieve precise estimates across all quintiles and there seems to be some random fluctuations between some of the quintiles. Thus, the exact quintile threshold should be interpreted with caution, and more emphasis should be placed on the general trends. There were limited and selective data in the dietary recall that could result in biases.

In conclusion, for middle-aged adults in the United Kingdom, sustained dietary improvement is predicted to increase life expectancy by about 3 years for both females and males. Importantly, for those with the least healthy dietary patterns, change to the longevity-associated dietary pattern is predicted to translate into approximately 10 years gain in life expectancy. Changing from an unhealthy dietary pattern to eating in line with the Eatwell Guide was associated with an 8 year life expectancy gain. Gains in life expectancy are lower the longer the delay in the initiation of dietary improvements, but even for those initiating dietary change at age 70 years, the gain in life expectancy is about half of that achieved by 40-year-old adults. The biggest gains in life expectancy are associated with increased intake of whole grains and nuts, and with reduced intake of sugar-sweetened beverages and processed meats. Our findings suggest that these food groups should be specific targets for clinicians in the guidance of patients and policymakers in developing public health policy.

## Methods

The study complies with all relevant ethical regulations (with approval obtained by UK Biobank from the National Health Service National Research Ethics Service (reference 11/NW/0382)). All data included are

from participants who provided written informed consent for use of their data. Detailed methods beyond the shortened description in this Brief Communication are provided in Supplementary Information.

## Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

## Data availability

Requests for the dataset can be sent through UK Biobank.

## Code availability

The R code is available in Supplementary Information.

## References

1. Global Burden of Disease Compare. Institute for Health Metrics and Evaluation <http://vizhub.healthdata.org/gbd-compare> (2020).
2. *Transforming Our World: The 2030 Agenda for Sustainable Development* (United Nations, 2015).
3. GBD. Global, regional, and national age–sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1736–1788 (2018).
4. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* <https://www.ncbi.nlm.nih.gov/pubmed/30954305> (2019).
5. Willett et al. Food in the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable food systems. *Lancet* **393**, 447–492 (2019).
6. NHS England. The Eatwell Guide. <https://www.nhs.uk/live-well/eat-well/food-guidelines-and-food-labels/the-eatwell-guide/> (2022).
7. Scheelbeek et al. Health impacts and environmental footprints of diets that meet the Eatwell Guide recommendations: analyses of multiple UK studies. *BMJ Open* **10**, e037554 (2020).
8. Cookson et al. Using cost-effectiveness analysis to address health equity concerns. *Value Health* **20**, 206–212 (2017).
9. Fadnes et al. Estimating impact of food choices on life expectancy: a modeling study. *PLoS Med.* **19**, e1003889 (2022).
10. Aune et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose–response meta-analysis of prospective studies. *Int. J. Epidemiol.* **46**, 1029–1056 (2017).
11. Schwingshackl et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. *Am. J. Clin. Nutr.* **105**, 1462–1473 (2017).
12. Aune et al. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. *BMJ* **353**, i2716 (2016).
13. Aune et al. Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies. *BMC Med.* **14**, 207 (2016).
14. Zeraatkar et al. Red and processed meat consumption and risk for all-cause mortality and cardiometabolic outcomes: a systematic review and meta-analysis of cohort studies. *Ann. Intern. Med.* **171**, 703–710 (2019).
15. Abete et al. Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality: a meta-analysis of cohort studies. *Br. J. Nutr.* **112**, 762–775 (2014).
16. Schwingshackl et al. Food groups and intermediate disease markers: a systematic review and network meta-analysis of randomized trials. *Am. J. Clin. Nutr.* **108**, 576–586 (2018).



17. Life expectancy at birth and selected older ages. Office for National Statistics <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/lifeexpectancyatbirthandselectedolderages> (2020).
18. Oeppen et al. Demography. Broken limits to life expectancy. *Science* **296**, 1029–1031 (2002).
19. UK Government. Government Food Strategy. <https://www.gov.uk/government/publications/government-food-strategy/government-food-strategy> (2022).
20. Davey et al. Levelling up health: a practical, evidence-based framework for reducing health inequalities. *Public Health Pract.* **4**, 100322 (2022).

## Acknowledgements

UK Biobank was established by the Wellcome Trust Medical Research Council, Department of Health, Scottish Government and Northwest Regional Development Agency. It has had funding from the Welsh assembly government and the British Heart Foundation. We thank the participants for their contributions. K.M.L. is supported by a National Health and Medical Research Council Emerging Leadership Fellowship (APP1173803). E.J.A. is supported by Helse Vest through the project ATLAS4LAR. This study was supported by Trond Mohn Foundation (grant number TMS2019TMT02). The hosting for the computations was performed on the Norwegian Research and Education Cloud (NREC), using resources provided by the University of Bergen and the University of Oslo (<http://www.nrec.no/>). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the paper.

## Author contributions

L.T.F., C.C.-M., F.K.H., J.P.P., K.A.J. and J.C.M. designed the study. L.T.F., C.C.-M., J.-M.Ø., S.P.-S. and Ø.A.H. conducted the statistical analysis. R.B., E.J.A. and Ø.A.H. contributed to the modelling. L.T.F. wrote the first draft. C.C.-M., J.-M.Ø., S.P.-S., K.M.L., F.K.H., J.P.P., R.B., E.J.A., Ø.A.H., K.A.J. and J.-M.Ø. critically revised the paper. L.T.F., C.C.-M. and J.-M.Ø. are the guarantors of the paper and accept full responsibility for the work and/or the conduct of the study, had access to the data and controlled the decision to publish. The corresponding author attests

that all listed authors meet authorship criteria and that no authors meeting the criteria have been omitted.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s43016-023-00868-w>.

**Correspondence and requests for materials** should be addressed to Lars T. Fadnes.

**Peer review information** *Nature Food* thanks Amanda Adler, Matthew Landry and Fred Tabung for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- |                                     |                                     |  |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A description of all covariates tested   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings   |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated   |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

### Reporting on sex and gender

Sex-specific estimates are provided. UKBiobank included 56% females among over 500,000 participants.

### Population characteristics

Age, sex and population indicators are included in the model. UKBiobank participants were aged 37-73 years at baseline

### Recruitment

UK Biobank is a prospective cohort study. A total of over 500,000 participants aged 37-73 years at baseline were enrolled, from the general population. In brief, between 2006 and 2010, participants attended one of 22 assessment centres across Scotland, England, and Wales. All participants completed a touch-screen questionnaire, had physical measurements taken, and provided blood, urine, and saliva samples at baseline. A subset of 467,354 participants in UK Biobank for whom diet was assessed at least once using the web-based 24-hour dietary questionnaire Oxford WebQ were included in this study (Text S1, Table S1).

### Ethics oversight

This study was performed under generic ethical approval obtained by UK Biobank from the National Health Service National Research Ethics Service (approval letter ref 11/NW/0382, 17 June 2011).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

### Sample size

See below

### Data exclusions

See below

### Replication

N/A

### Randomization

N/A

### Blinding

N/A

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

### Study description

UK Biobank is a prospective cohort study (quantitative). Our study used modeling with these background data.

### Research sample

A subset of 467,354 participants in UK Biobank for whom diet was assessed at least once using the web-based 24-hour dietary questionnaire Oxford WebQ were included in this study (56% females).

### Sampling strategy

A population-based random sample from >500,000 participants aged 37-73 years at baseline were enrolled, from the general population. In brief, between 2006 and 2010, participants attended one of 22 assessment centres across Scotland, England, and Wales. All participants completed a touch-screen questionnaire, had physical measurements taken, and provided blood, urine, and saliva samples at baseline.

### Data collection

The baseline touchscreen questionnaire that was completed by participants at the assessment centre, was based on the food frequency questionnaire (FFQ), which included 29 items about diet and 18 questions about alcohol. The questionnaire included data on the frequency of consumption of the main food groups over the previous year, including fruits and vegetables, fish, meat, and cheese (details in Table S4). A 24-hour recall-based method, based on the Oxford WebQ, which captured information on up to 206 food and 32 drink items, was introduced towards the end of the recruitment period. Thus, participants recruited between April 2009 and September 2010 completed this at their assessment centre baseline visit. In addition, between February 2011 and June 2012, there were 4 cycles, separated by 3-4 months, where participants were invited via email to complete the 24-hour dietary recall at home. Over 200,000 participants completed at least one 24-hour recall. Further details about the dietary assessments, including

reproducibility and agreement between the two methods have been published. In the present study, we used data from the 24-hour recall (Oxford WebQ) to assess adherence to the recommendations on the intakes of nuts, eggs, and sugar-sweetened drinks. We used FFQ data for fruits and vegetables, whole and refined grain, fish, dairy, processed and unprocessed meat and vegetable oils recommendations where the cut-offs are described as intake 'per week' so as not to over or underestimate consumption of these foods. The participants were blinded to the hypotheses of this study.

Timing	Participants were recruited between April 2009 and September 2010 completed this at their assessment centre baseline visit. In addition, between February 2011 and June 2012, there were 4 cycles, separated by 3-4 months
Data exclusions	Persons without dietary assessments or heart disease diagnoses were excluded (approximately 81,645).
Non-participation	Of >500,000 participants enrolled in UK Biobank, 467,354 participants had dietary assessments and were included in this study (while the remainder were excluded)
Randomization	No randomization was conducted for the study.

## Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.
Research sample	Describe the research sample (e.g. a group of tagged <i>Passer domesticus</i> , all <i>Stenocereus thurberi</i> within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.
Sampling strategy	Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection	Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale	Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work?  Yes  No

## Field work, collection and transport

Field conditions	N/A
Location	N/A
Access & import/export	N/A
Disturbance	N/A

## Reporting for specific materials, systems and methods



We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

- n/a  Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Clinical data
- Dual use research of concern

## Methods

- n/a  Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

## Antibodies

Antibodies used

N/A

Validation

N/A

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

N/A

Authentication

N/A

Mycoplasma contamination

N/A

Commonly misidentified lines  
(See [ICLAC](#) register)

N/A

## Palaeontology and Archaeology

Specimen provenance

N/A

Specimen deposition

N/A

Dating methods

N/A

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

For laboratory animals, report species, strain and age OR state that the study did not involve laboratory animals.

Wild animals

Provide details on animals observed in or captured in the field; report species and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Reporting on sex

Indicate if findings apply to only one sex; describe whether sex was considered in study design, methods used for assigning sex. Provide data disaggregated for sex where this information has been collected in the source data as appropriate; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex-based analyses where performed, justify reasons for lack of sex-based analysis.

Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

## Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration  Provide the trial registration number from [ClinicalTrials.gov](#) or an equivalent agency.

Study protocol  Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection  Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes  Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

## Dual use research of concern

Policy information about [dual use research of concern](#)

### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

- | No                                  | Yes   |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Public health              |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> National security          |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Crops and/or livestock     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Ecosystems                 |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Any other significant area |

### Experiments of concern

Does the work involve any of these experiments of concern:

- | No                                  | Yes  |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Demonstrate how to render a vaccine ineffective                             |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Confer resistance to therapeutically useful antibiotics or antiviral agents |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Enhance the virulence of a pathogen or render a nonpathogen virulent        |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Increase transmissibility of a pathogen                                     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Alter the host range of a pathogen  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Enable evasion of diagnostic/detection modalities                           |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Enable the weaponization of a biological agent or toxin                     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Any other potentially harmful combination of experiments and agents         |

## ChIP-seq

### Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links  For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, may remain private before publication. provide a link to the deposited data.

Files in database submission  Provide a list of all files available in the database submission.

Genome browser session  Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents. (e.g. [UCSC](#))

## Methodology

Replicates	<i>Describe the experimental replicates, specifying number, type and replicate agreement.</i>
Sequencing depth	<i>Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.</i>
Antibodies	<i>Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.</i>
Peak calling parameters	<i>Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.</i>
Data quality	<i>Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.</i>
Software	<i>Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.</i>

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	<i>Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.</i>
Instrument	<i>Identify the instrument used for data collection, specifying make and model number.</i>
Software	<i>Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.</i>
Cell population abundance	<i>Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.</i>
Gating strategy	<i>Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.</i>

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type	<i>Indicate task or resting state; event-related or block design.</i>
Design specifications	<i>Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.</i>
Behavioral performance measures	<i>State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).</i>

## Acquisition

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI  Used  Not used

## Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

## Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis:  Whole brain  ROI-based  Both

Statistic type for inference (See [Eklund et al. 2016](#))

Correction

## Models & analysis

n/a | Involved in the study

Functional and/or effective connectivity

Graph analysis

Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis